hCAIX-IN-13

hCAIX-IN-13 (Pt2) is an inhibitor of CAIX (arbonic anhydrase IX) with an IC50 value of 6.57 μM. hCAIX-IN-13 inhibits growth of cancer cells and induces cell apoptosis, it can be used for the research of cancer[1].

Signaling Pathways >> Apoptosis >> Apoptosis

Research Areas >> Cancer

IC50: 6.57 μM (CAIX)[1]

hCAIX-IN-13 (10 and 20 μM; 24 h) effectively attenuates extracellular acidification through the inhibited activity of the cellular CAIX expression[1]. hCAIX-IN-13 (20 and 40 μM; 24 h) affects CAIX expression[1]. hCAIX-IN-13 (0-200 μM; 24 h) shows high cytotoxicity to cancer cell lines[1]. hCAIX-IN-13 (5-15 μM; 24 h) promotes the production of cellular ROS[1]. hCAIX-IN-13 (5-20 μM; 48 h) induces cell apoptosis[1]. Western Blot Analysis[1] Cell Line: MDA-MB-231 cell line Concentration: 20 and 40 μM Incubation Time: 24 hours Result: Dose-dependently inhibited the expression level of cellular CAIX. Cell Cytotoxicity Assay[1] Cell Line: Hela, A549, MDA-MB 231, HLF and LO2 cell lines Concentration: 0-200 μM Incubation Time: 48 hours Result: Showed cytotoxicity to Hela, A549, MDA-MB 231, normal cell HLF and normal cell LO2 with IC50s of 31.64, 30.45, 12.67, 21.64 and ＞100 μM, respectively. Apoptosis Analysis[1] Cell Line: MDA-MB-231 cell line Concentration: 5-20 μM Incubation Time: 48 hours Result: Dose-dependently induced the early apoptotic stage.

[1]. Yang J, et al. NIR phosphorescent cyclometalated platinum (II) complexes with CAIX targeted and nuclear penetration as potent anticancer theragnostic agents. Eur J Med Chem. 2022 Aug 31;243:114702.